Pratia accelerates U.S. expansion with majority investment in P1 Trials

Linking Europe and the U.S., this collaboration expands access to innovative cancer therapies for millions of patients.

Pratia LLC, part of Humaneva Group, today announced the acquisition of a majority stake in P1 Trials, a U.S.-based early phase oncology clinical research network.

P1 Trials, with its community-based oncology practices in the states of WA, TX and IN, brings advanced early-phase oncology studies closer to where patients receive care. The company enables community oncology practices by providing the infrastructure and support needed to conduct early-phase trials through a unified global standard.

Through this investment, Pratia and P1 are establishing one of the few global research ecosystems dedicated exclusively to early-phase oncology, connecting North America and Europe to accelerate the development of next-generation cancer treatments. United by a shared mission, Pratia and P1 Trials are deeply patient-centric, and will continue working to bring innovative therapies to patients wherever they live.

Pratia currently reaches more than 65 million Patients across Europe through its integrated oncology research sites. The addition of P1’s U.S. network extends that reach and enhances both companies’ ability to deliver innovative studies in the world’s largest oncology research market.

This investment strengthens Pratia’s presence in the United States, and underscores its commitment to accelerating new treatment development through closer collaboration with practicing oncologists.

According to the American Association for Cancer Research, approximately 18.6 million cancer survivors were living in the U.S. as of January 2025, while the World Health Organization estimates 3.7 million new cancer cases annually across Europe.

“By unifying our scientific rigor, operational standards, and patient care models, we’re building a seamless early-phase oncology network that operates with the same precision and excellence – from community practices in the U.S. to leading research centers across Europe. This alignment accelerates innovation and ensures patients everywhere gain faster access to tomorrow’s therapies.” – said Julio Peguero, MD, President of P1 Trials.

The creation of this unified early-phase network aims to address the urgent global need for faster development and wider access to innovative therapies.

Ron Carozza, PharmD, CEO, P1 Trials, concludes: “We share the same values as Pratia, and with their global expertise and resources, we can accelerate this mission even further. Together, we will bring the latest cancer science directly to patients in their communities- faster“.